The efficacy of ifosfamide (6o mg/kg, d1-5) and vindesine (3 mg/m 2, d1+(5)) as second line chemotherapy was investigated in 26 male patients (pts) with small cell lung cancer (SCLC) resistant ( pts) to first line therapy or relapsing (17pts) after transient remission. Median age of the pts was 53 years, range 33-74, median perfor mance status 7o%, range 4c-leo. Pretreatment cot sisted of either adriamycin (epirubicin)/cyclo--phosphamide/vineristins and etoposide/cisplatin or CCNU/eteposi~e/msthotrexats
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• thoracic irradiation. To date, 23 pts (7 pts with limited disease (LD), 16 pts with extensive disease (EO) are evaluable for response. 2 pts (one with tumor relapse in an area of prior irradiation, one with hepatic metastasis) achieved second complete remission (CR) lasting 21 and 33 weeks,respectively. Survival from sta~ of ifosfamide/vindesine treatment in these pts 46 and 51+ weeks. Partial remissions (PR) were induced in 7 pts (4 LD, 3 ED). Median remission duration in PR pts was 19 weeks (range 13-33), median survival 3o weeks (range 13-52)o7 pts win disease stabilization had a median survival of 18 weeks, range 8-43. 7 pts (ED) did not respond and survived 4-22 weeks, median 11. Response ra~ (CR+PR) of relapsing SCLC was 47% as compared to 22% in primarily resistant tumor. Interestingly, 4 pts with relapse in an area of prior irradiat~-on achieved CR or PR. Oue to side effects as ur~ toxicity, polyneuropathy, myelosuppression and central nervous effects, dosis had to be reduced in 2 pts, and treatment was stopped in 2 pts. Dec. 1984 until Oct. 1985 31 patients (pts) with proven NSCLC were treated according to their performance status (Karnofsky) with the combination of Ifosfamide, Mitomycin C and Vindesine. We treated 27 men aged 46-75 years (mean 59) with a Karnofsky-index between 60 and i00 % and 4 women aged 46-57 years (mean 51) with a Karnofsky-index between 60 and 90 %. The dosage of Ifosfamide and Vindesine was adapted according to the performance status: Karnofsky 90-100: Ifosfamide 1,8 g/m 2 day I-5, Vindasine 2 mg day 3, 4 and 5. Karnofsky 60-80: Ifosfamide 1,5 g/m 2 day I-5, Vindesine 1,5 mg day 3, 4 and 5. Mitomyein C was given unadapted with I0 mg/m 2 day i. Divided into the histological subtypes we found 15 cases of squamous cell carcinoma, 9 cases of adenocarcinoma and 7 cases of large cell carcinoma. 8 pts had extensive disease I and 23 pts had extensive disease II. Cases of limited disease weren't accepted for the study. From the 31 pts 6 are not evaluable (2 to early for evaluation, 3 pts died during the first 4 weeks of treatment, i pat. is lost to follow up). 7 of 25 pts had received prior chemotherapy, prior irradiation therapy or surgical treatment. 1 of the 18 pts without prior trea~ ment reached CR, 6 pts reached PR, 3 showed MR (less than 50 % tumor regression). 5 showed stable disease and 1 pat. experienced progressive disease. In the group of pretreated pts l~PPwas reached, 5 pts showed no change and i pat. had progressive disease. Final remarks concerning remission duration and survival can't be made, recruitment for this study will c6ntinue. Toxicity was tolerable, only 5 nentropenic episodes with leucocytes lowe~ than 1G/I were observed, nephrotoxicity was absent. In 1 pat. we observed pulmonary toxicity of clinical evidence. In comparison to DDP-containing combinations the response rates are nearly the same, GI-toxicity was less severe in our regimen.
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TREATMENT OF UNRESECTABLE NON SMALL CELL LUNG CANCER (NSCLC) WITH CIS-PLATINUM/IFOSFAMIDE/VINDESIN M. Schroeder, W. Wellens, M. Westerhausen From July 1982 to October 1984 42 patients (pts) with histologically proven NSCLC were treated with a combination of cis-platinum/ifosfamide/vindesin. We treated 37 men aged 41-73 years (mean 55) with a performance status between 50-90 % and 5 women aged 51-68 years (mean 57) with a performance status of 60-90 %. 40 pts were evaluable for response. 3 pts had limited disease, 16 pts had extensive disease I and 21 hat extensive disease II. According to histologic subtypes we found 22 cases of squamous cell carcinoma, 10 cases of adenocarcinoma and 8 cases of large cell carcinoma. 15 pts had undergone recent pretreatment (i CT, 10p., 5 Irr., 60p. + Irr., 10p. +CT, i Op. + Irr. + CT~. We reached 3 CR, 4 PR, 6 MR (less than 50 % tumor regression), 12 pts had no change and 15 pts had progressive disease. The duration of CR in complete responders is 30 +, 25 + and 19 + months. Initial progression of the tumor was often seen in pretreated pts.. Toxicity was very high for this regimen, especially severe CI-toxicity (Grad 3-4 W~O) occured in more than 70 % of the pts. Lifethreatening infections were seen in 7 cases, 1 patient died due to septicaemia. One patient died after receiving 4 cycles of this regimen due to renal failure. There was no increase in response rates reachable by combining the three most effective cytotoxic drugs in NSCLC treatment. Still 3 of 40 pts are living in complete remission.
